Patent · US Active

Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer

US11590130B2 · kind B2 · utility

0Cited by

1References

11Claims

0Family size

Assignee

NOVIGA RESEARCH AB · SE

Inventors

Marita Hogberg · Tullinge, SE
Stefan Rehnmark · Tullinge, SE

Key dates

Filing date	Apr 4, 2019
Grant date	Feb 28, 2023
Priority date	—
Expiry date	May 5, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods and combination therapies for treating, preventing, and/or delaying the onset and/or development of cancer using a tubulin polymerization inhibitor such as a compound of formula I, or a pharmaceutically acceptable salt thereof, and a poly (ADP-ribose) polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt thereof, are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.